Tagged with P

Pró Genéricos When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote it.” At that time, generics penetration was around 10.5% – now it’s around 20%. Does this reflect some fundamental change…

Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…

Productos Roche S.A. What has been the evolution of Roche’s operations in Colombia’s over the course of its proud 52-year history here? As with almost all pharmaceutical companies with commercial operations in Latin America, we began our business here in Colombia with a production plant. The plant has closed since 1997 as our…

OEP Philippines Mr. Chang, can you please give an overview of the establishment of OEP Philippines and the company’s current activities here? OEP Philippines started by acquiring the operations of Elan Pharma Phils, an Irish company. In 2003, when Elan Pharma decided to dispose of their subsidiary in the Philippines, Mr. Peter…

Otsuka (Philippines) Pharmaceutical You were appointed President and General Manager of Otsuka Philippines in 2008. Can you please start by giving to our readers an overview of Otsuka activities in the country as well as the company’s biggest achievements since you have been heading the company? Otsuka Philippines was incorporated in December 1997…

Sanofi-Aventis Philippines Mr. Realuyo, you have been in sanofi-aventis for 16 years, three of which were at the head. What have been the major achievements that the company has reached since your appointment as President & General Manager? In the last years, the pharmaceutical industry has been able to engage with the…

Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…

Ipsen Farmaceutica BV Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen, what has been the professional trajectory that has brought you to the head of this local affiliate? I came here…

NEPROFARM In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines are the medication of choice in the Netherlands. Most people will have some OTC medicines in his cabinet and indeed,…

Dompe You recently declared that in a context of new emerging challenges for pharmaceutical companies, those who would survive would not be the strongest ones but the most responsive to change. Indeed, having led Dompé Group through this period of changes, you originated a re-organization of the group. Could you give…

Assign Group Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it was simply the location of the CEO who had been living there for a while, bein the medical director of…

Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…